Altimmune (ALT)
(Delayed Data from NSDQ)
$6.23 USD
-0.55 (-8.11%)
Updated Jan 14, 2025 04:00 PM ET
After-Market: $6.23 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ALT 6.23 -0.55(-8.11%)
Will ALT be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for ALT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALT
Altimmune Stock Up More Than 25% in a Month: Here's Why
Brookdale Senior (BKD) Q2 Occupancy Jumps, Growth Trend Persists
ALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade
Other News for ALT
Undercovered Dozen: Fannie Mae, Civitas Resources, LifeVantage, ZenaTech +
Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion
FDA issues draft guidance on developing weight loss drugs
Closing Bell Movers: Cal-Maine Foods up 5% on Q2 results
Closing Bell Movers: Cal-Maine Foods up 5% on Q2 results